PT-141: Libido Starts In The Brain
Unlike most sexual wellness medications, PT-141 acts on the central nervous system. Here's what makes it different — and who it's for.
Most medications for sexual function work on blood flow. PT-141 works on desire itself. It activates melanocortin receptors in the central nervous system — the pathways that drive arousal at its origin.
Who it's for
Patients who have addressed the physical components of sexual function but still feel a missing piece. Women and men both report meaningful results, often within the first few uses.
What to expect
PT-141 is dosed as needed, not daily. Effects build over hours, and most patients find the experience subtle, natural, and connected — not pharmaceutical. Side effects are typically mild and short-lived: flushing, mild nausea, or transient blood pressure changes. As with any prescribed peptide, supervision matters.
Sources & references
Peer-reviewed studies, clinical guidelines, and regulatory documents used to write this article.
- 1.Vyleesi (bremelanotide) Prescribing Information.— U.S. Food and Drug Administration, 2019.
- 2.Kingsberg SA et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT). Obstet Gynecol. 2019;134(5):899-908.— Obstetrics & Gynecology, 2019.
- 3.Pfaus J et al. The melanocortin system and sexual function. Pharmacol Biochem Behav. 2007;86(2):277-288.— Pharmacology Biochemistry and Behavior, 2007.
How this article was written: Researched and drafted by the Valora Rx editorial team using current peer-reviewed literature and clinical practice guidelines from bodies including the Endocrine Society, AUA, NAMS, ACOG, and FDA. This article is informational and is not a substitute for individualized medical advice from your physician. Read our editorial standards →
